文献速递垂体与肾上腺疾病

左酮康唑:酮康唑的2S,4R对映体——治疗库欣综合征的新型类固醇生成抑制剂

Levoketoconazole, the 2S,4R Enantiomer of Ketoconazole, a New Steroidogenesis Inhibitor for Cushing's Syndrome Treatment.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

该研究在体外比较左酮康唑与消旋酮康唑对肾上腺皮质和垂体腺瘤细胞的作用。左酮康唑抑制皮质醇生成的效力更强,在HAC15细胞中IC50为0.300 μM,而消旋酮康唑为0.611 μM(P < 0.0001)。左酮康唑还可能抑制ACTH分泌和垂体腺瘤细胞生长。

要点

  • 左酮康唑抑制HAC15细胞皮质醇的IC50为0.300 μM,强于消旋酮康唑的0.611 μM。
  • 原发性肾上腺皮质培养中左酮康唑的IC50在0.00578-0.140 μM间波动,个体差异达24倍。
  • 左酮康唑在10 μM时抑制AtT20细胞生长54%和ACTH分泌38%。

核心结论

  • 左酮康唑强效抑制肾上腺皮质细胞皮质醇生成,但不同标本的抑制程度存在差异。
  • 左酮康唑抑制肾上腺类固醇生成的效力强于消旋酮康唑,并可能抑制ACTH分泌和垂体腺瘤细胞生长。
  • 左酮康唑是治疗库欣综合征有前景的新型药物。

研究设计与样本

  • 体外研究,使用HAC15细胞、15例原发性人肾上腺皮质肿瘤培养(含或不含ACTH)、小鼠AtT20细胞和2例人垂体促肾上腺皮质激素腺瘤培养。
  • 细胞与左酮康唑或消旋酮康唑(0.01-10 μM)孵育,用化学发光免疫分析法测皮质醇和ACTH,用液相色谱-串联质谱(LC-MS/MS)分析类固醇谱。

主要发现

  • 在HAC15细胞中,左酮康唑抑制皮质醇的IC50为0.300 μM,消旋酮康唑为0.611 μM(P < 0.0001)。
  • 原发性肾上腺皮质培养中左酮康唑抑制基础皮质醇的IC50范围为0.00578-0.140 μM,波动达24倍,其中2例患者对左酮康唑的敏感性高于消旋酮康唑(分别高2.1倍和3.7倍)。
  • LC-MS/MS分析显示左酮康唑比消旋酮康唑更有效地抑制皮质醇和其他类固醇谱成分。
  • 在AtT20细胞中,左酮康唑10 μM时抑制细胞生长54%和ACTH分泌38%。
  • 在2例原代人垂体促肾上腺皮质激素腺瘤培养中,左酮康唑抑制其中1例的细胞数量44%(P < 0.001)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Racemic ketoconazole (RK) is a steroidogenesis inhibitor used for treatment of Cushing's syndrome. Levoketoconazole (COR-003), the pure 2S,4R enantiomer, is potentially more potent and safe compared to RK. We compared in vitro effects of levoketoconazole and RK on adrenocortical and pituitary adenoma cells. MATERIALS AND METHODS: HAC15 cells and 15 primary human neoplastic adrenocortical cultures (+/- ACTH), and murine (AtT20) and human corticotroph adenoma cultures were incubated with levoketoconazole or RK (0.01-10 µM). Cortisol and ACTH were measured using a chemiluminescence immunoassay system, and steroid profiles by liquid chromatography-tandem mass spectrometry (LC-MS/MS). RESULTS: In HAC15, levoketoconazole inhibited cortisol at lower concentrations (IC50: 0.300 µM) compared to RK (0.611 µM; P < 0.0001). IC50 values of levoketoconazole for basal cortisol production in primary adrenocortical cultures varied over a 24-fold range (0.00578-0.140 µM), with 2 patients having a higher sensitivity for levoketoconazole vs RK (2.1- and 3.7-fold). LC-MS/MS analysis in selected cases revealed more potent inhibition of cortisol and other steroid profile components by levoketoconazole vs RK. In AtT20, levoketoconazole inhibited cell growth and ACTH secretion (10 µM: -54% and -38%, respectively), and levoketoconazole inhibited cell number in 1 of 2 primary human corticotroph pituitary adenoma cultures (-44%, P < 0.001). CONCLUSION: Levoketoconazole potently inhibits cortisol production in adrenocortical cells, with a variable degree of suppression between specimens. Levoketoconazole inhibits adrenal steroid production more potently compared to RK and might also inhibit ACTH secretion and growth of pituitary adenoma cells. Together with previously reported potential advantages, this indicates that levoketoconazole is a promising novel pharmacotherapy for Cushing's syndrome.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Creemers SG, Feelders RA, de Jong FH, et al. Levoketoconazole, the 2S,4R Enantiomer of Ketoconazole, a New Steroidogenesis Inhibitor for Cushing's Syndrome Treatment. J Clin Endocrinol Metab. 2021. PMID: 33399817. doi:10.1210/clinem/dgaa989

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。